|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PRR3 |
Gene summary for PRR3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PRR3 | Gene ID | 80742 |
| Gene name | proline rich 3 | |
| Gene Alias | CAT56 | |
| Cytomap | 6p21.33 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | B3KQA4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 80742 | PRR3 | LZE4T | Human | Esophagus | ESCC | 4.77e-02 | 7.59e-02 | 0.0811 |
| 80742 | PRR3 | LZE7T | Human | Esophagus | ESCC | 9.95e-03 | 1.72e-01 | 0.0667 |
| 80742 | PRR3 | LZE24T | Human | Esophagus | ESCC | 1.40e-15 | 2.29e-01 | 0.0596 |
| 80742 | PRR3 | LZE6T | Human | Esophagus | ESCC | 4.20e-03 | 1.64e-01 | 0.0845 |
| 80742 | PRR3 | P1T-E | Human | Esophagus | ESCC | 1.63e-13 | 6.46e-01 | 0.0875 |
| 80742 | PRR3 | P2T-E | Human | Esophagus | ESCC | 4.08e-25 | 4.25e-01 | 0.1177 |
| 80742 | PRR3 | P4T-E | Human | Esophagus | ESCC | 9.69e-12 | 3.97e-01 | 0.1323 |
| 80742 | PRR3 | P5T-E | Human | Esophagus | ESCC | 2.44e-08 | 1.86e-01 | 0.1327 |
| 80742 | PRR3 | P8T-E | Human | Esophagus | ESCC | 6.37e-12 | 1.64e-01 | 0.0889 |
| 80742 | PRR3 | P9T-E | Human | Esophagus | ESCC | 6.76e-08 | 1.45e-01 | 0.1131 |
| 80742 | PRR3 | P10T-E | Human | Esophagus | ESCC | 7.95e-16 | 2.76e-01 | 0.116 |
| 80742 | PRR3 | P11T-E | Human | Esophagus | ESCC | 4.67e-08 | 1.99e-01 | 0.1426 |
| 80742 | PRR3 | P12T-E | Human | Esophagus | ESCC | 3.94e-21 | 3.29e-01 | 0.1122 |
| 80742 | PRR3 | P15T-E | Human | Esophagus | ESCC | 7.70e-09 | 1.68e-01 | 0.1149 |
| 80742 | PRR3 | P16T-E | Human | Esophagus | ESCC | 9.22e-19 | 3.21e-01 | 0.1153 |
| 80742 | PRR3 | P17T-E | Human | Esophagus | ESCC | 1.51e-08 | 3.91e-01 | 0.1278 |
| 80742 | PRR3 | P20T-E | Human | Esophagus | ESCC | 1.65e-04 | 6.46e-02 | 0.1124 |
| 80742 | PRR3 | P21T-E | Human | Esophagus | ESCC | 8.51e-07 | 1.32e-01 | 0.1617 |
| 80742 | PRR3 | P22T-E | Human | Esophagus | ESCC | 5.59e-20 | 4.04e-01 | 0.1236 |
| 80742 | PRR3 | P23T-E | Human | Esophagus | ESCC | 4.80e-10 | 2.12e-01 | 0.108 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
| GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
| GO:00435884 | Cervix | CC | skin development | 71/2311 | 263/18723 | 8.04e-11 | 1.46e-08 | 71 |
| GO:00302164 | Cervix | CC | keratinocyte differentiation | 42/2311 | 139/18723 | 1.74e-08 | 1.28e-06 | 42 |
| GO:00099137 | Cervix | CC | epidermal cell differentiation | 53/2311 | 202/18723 | 5.48e-08 | 3.25e-06 | 53 |
| GO:00181493 | Cervix | CC | peptide cross-linking | 10/2311 | 35/18723 | 7.99e-03 | 4.18e-02 | 10 |
| GO:000854413 | Cervix | HSIL_HPV | epidermis development | 38/737 | 324/18723 | 1.92e-09 | 3.23e-07 | 38 |
| GO:003021611 | Cervix | HSIL_HPV | keratinocyte differentiation | 22/737 | 139/18723 | 2.53e-08 | 2.18e-06 | 22 |
| GO:004358813 | Cervix | HSIL_HPV | skin development | 31/737 | 263/18723 | 5.32e-08 | 3.89e-06 | 31 |
| GO:000991313 | Cervix | HSIL_HPV | epidermal cell differentiation | 26/737 | 202/18723 | 1.10e-07 | 7.15e-06 | 26 |
| GO:004206015 | Cervix | HSIL_HPV | wound healing | 40/737 | 422/18723 | 2.80e-07 | 1.61e-05 | 40 |
| GO:00181491 | Cervix | HSIL_HPV | peptide cross-linking | 8/737 | 35/18723 | 5.08e-05 | 1.26e-03 | 8 |
| GO:00435888 | Esophagus | ESCC | skin development | 163/8552 | 263/18723 | 6.48e-08 | 1.14e-06 | 163 |
| GO:000854410 | Esophagus | ESCC | epidermis development | 193/8552 | 324/18723 | 2.87e-07 | 4.19e-06 | 193 |
| GO:004206027 | Esophagus | ESCC | wound healing | 243/8552 | 422/18723 | 4.62e-07 | 6.25e-06 | 243 |
| GO:000991310 | Esophagus | ESCC | epidermal cell differentiation | 122/8552 | 202/18723 | 1.69e-05 | 1.51e-04 | 122 |
| GO:00302167 | Esophagus | ESCC | keratinocyte differentiation | 86/8552 | 139/18723 | 8.53e-05 | 6.19e-04 | 86 |
| GO:004206020 | Oral cavity | OSCC | wound healing | 237/7305 | 422/18723 | 4.51e-13 | 2.18e-11 | 237 |
| GO:00435887 | Oral cavity | OSCC | skin development | 143/7305 | 263/18723 | 2.77e-07 | 4.27e-06 | 143 |
| GO:00085449 | Oral cavity | OSCC | epidermis development | 171/7305 | 324/18723 | 2.89e-07 | 4.43e-06 | 171 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PRR3 | SNV | Missense_Mutation | rs751749669 | c.431N>T | p.Pro144Leu | p.P144L | P79522 | protein_coding | deleterious_low_confidence(0.04) | benign(0.006) | TCGA-A8-A07B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PRR3 | SNV | Missense_Mutation | novel | c.424A>G | p.Thr142Ala | p.T142A | P79522 | protein_coding | tolerated_low_confidence(0.12) | benign(0.162) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PRR3 | SNV | Missense_Mutation | novel | c.530N>T | p.Ala177Val | p.A177V | P79522 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.448) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PRR3 | SNV | Missense_Mutation | novel | c.466T>A | p.Ser156Thr | p.S156T | P79522 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.82) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PRR3 | SNV | Missense_Mutation | novel | c.412C>A | p.Leu138Ile | p.L138I | P79522 | protein_coding | deleterious_low_confidence(0.02) | benign(0.024) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| PRR3 | SNV | Missense_Mutation | novel | c.381N>T | p.Gln127His | p.Q127H | P79522 | protein_coding | deleterious_low_confidence(0.01) | benign(0.276) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PRR3 | SNV | Missense_Mutation | novel | c.187C>T | p.Pro63Ser | p.P63S | P79522 | protein_coding | deleterious_low_confidence(0.02) | benign(0.231) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PRR3 | SNV | Missense_Mutation | c.452T>C | p.Val151Ala | p.V151A | P79522 | protein_coding | tolerated_low_confidence(0.06) | benign(0.068) | TCGA-HU-A4GH-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PRR3 | deletion | Frame_Shift_Del | novel | c.448delC | p.Gln150ArgfsTer55 | p.Q150Rfs*55 | P79522 | protein_coding | TCGA-CD-A4MJ-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |